REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-24. Numbers and descriptions here follow the published literature rather than marketing material.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
== History == Thiobuscaline was first described in the scientific literature by Alexander Shulgin and Peyton Jacob III in 1984. Subsequently, it was described in greater detail by Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991.
On average, groups of people with "obese" BMIs may have a higher risk of developing illnesses like diabetes, hypertension, dyslipidemia (high cholesterol), liver disease, and some cancers. "Underweight" BMIs may indicate malnutrition or other health problems. However, BMI has limitations when used to describe individual health rather than describing populations of people.
The choice of starting material is key to the design of a purification process. In a plant or animal, a particular protein usually is not distributed homogeneously throughout the body; different organs or tissues have higher or lower concentrations of the protein. The use of only the tissues or organs with the highest concentration decreases the volumes needed to produce a given amount of purified protein. If the protein is present in low abundance, or if it has a high value, scientists may use recombinant DNA technology to develop cells that will produce large quantities of the desired protein (this is known as an expression system). Recombinant expression allows the protein to be tagged, e.g. by a His-tag or Strep-tag to facilitate purification, reducing the number of purification steps required. Analytical purification generally utilizes three properties to separate proteins. First, proteins may be purified according to their isoelectric points by running them through a pH-graded gel or an ion exchange column. Second, proteins can be separated according to their size or molecular weight via size exclusion chromatography or by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) analysis. Proteins are often purified by using 2D-PAGE and are then analysed by peptide mass fingerprinting to establish the protein identity. This is very useful for scientific purposes and the detection limits for protein are nowadays very low and nanogram amounts of protein are sufficient for their analysis.
Every building material contains traces of natural radioactive substances, especially 238uranium, 232thorium, and their decay products, and 40potassium. Solidified and effusive rocks such as granite, tuff, and pumice have higher levels of radioactivity. In contrast, sand, gravel, limestone, and natural gypsum (calcium sulfate dihydrate) have low levels of radioactivity. The European Union's Activity Concentration Index (ACI), developed in 1999, can be used to assess radiation exposure from building materials. It replaces the Leningrad summation formula, which was used in 1971 in Leningrad (St. Petersburg) to determine how much radiation exposure from building materials is permissible for humans. The ACI is calculated from the sum of the weighted activities of 40potassium, 226radium, and 232thorium. The weighting takes into account the relative harmfulness to humans. According to official recommendations, building materials with a European ACI value greater than "1" should not be used in large quantities.
perlatum's physiological responses are significantly influenced by water availability. The ability to maintain higher photosynthetic performance and pigment content in humid conditions suggests that P. perlatum is better adapted to environments with higher moisture levels. This adaptability makes P. perlatum useful as a bioindicator for monitoring ecological responses to climate change and varying moisture conditions in Mediterranean ecosystems. Lichenicolous (lichen-dwelling) fungi that have been recorded parasitising Parmotrema perlatum include Abrothallus parmotrematis, Briancoppinsia cytospora, Lichenoconium erodens, and Spirographa lichenicola.
Sources: en.wikipedia.org
RGFP966 is a histone deacetylase (HDAC) inhibitor, specifically acting as a highly selective HDAC3 inhibitor, with an IC50Tooltip half-maximal inhibitory concentration of 80 nM and no inhibition of other HDACs at concentrations of up to 15,000 nM or 20,000 nM. It enhances cognition, memory, and learning in rodents. The drug reverses age-related impairments in memory updating in rodents. In addition, it has been found to facilitate the extinction of drug-seeking behavior in a manner refractory to reinstatement in rodents. Conversely, unlike the pan-class I HDAC inhibitor RGFP963, RGFP966 failed to enhance consolidation of cued fear extinction in rodents, suggesting that HDAC1 and/or HDAC2 may be involved in this instead. Also unlike pan-class I HDAC inhibitors, which can enhance synaptogenesis, RGFP966 showed minimal effect in this regard. The drug increases brain-derived neurotrophic factor (BDNF) expression. Knockdown of HDAC2 and knockdown of HDAC3 have been found to increase BDNF expression, whereas knockdown of other HDACs did not do so. RGFP966 produces anti-inflammatory effects. It shows antidepressant-like effects against neuroinflammation-induced depression in rodents. Similarly to butyric acid (butyrate), RGFP966 ameliorates sleep deprivation-induced intestinal mucosa-induced damage in rodents. RGFP966 has neuroprotective and neurorestorative effects in preclinical research.
28 September – TikTok announced that it had shut down a misinformation network of 72 accounts targeting Ireland, that had over 94,000 followers, saying "the operators of the accounts posted divisive views in a bid to intensify social conflict." 29 September Gardaí launched a murder investigation after a woman in her 40s died following a violent attack at her home in County Offaly. A 16-year-old boy, known to the victim, was arrested at the scene. The attack was filmed and posted on social media. Homelessness figures were released, showing that there were 12,691 people homeless in Ireland in August – a 17% increase year-on-year – including a record 3,895 homeless children.
Lissencephaly A rare brain malformation where the cerebral cortex lacks normal folds (gyri), leading to developmental delay and seizures. Long-term depression (LTD) A long-lasting decrease in synaptic strength following low-frequency stimulation. Thought to be important in motor learning and memory pruning. Long-term memory Stored information retained for extended periods—from hours to years. Includes declarative (explicit) and non-declarative (implicit) forms. Long-term potentiation (LTP) A long-lasting enhancement in signal transmission between two neurons that results from their synchronous activation. A major cellular mechanism underlying learning and memory. Low-threshold spikes A burst of action potentials generated by the activation of low-threshold, T-type calcium channels in response to a small depolarization from a hyperpolarized membrane potential. Commonly observed in thalamic neurons, low-threshold spikes enable rhythmic firing and are important for sleep-related oscillations and sensory signal gating. Lower motor neuron A neuron that directly innervates skeletal muscle. Damage to these neurons causes flaccid paralysis, muscle atrophy, and loss of reflexes. LTP induction The process of initiating long-term potentiation through specific patterns of synaptic stimulation, such as high-frequency tetanic stimulation. Lucid dreaming A state during which the dreamer is aware that they are dreaming and may be able to exert control over the dream. Associated with increased prefrontal cortex activity.
=== January === 1 January – Police Scotland launch a murder investigation following the death of a 38-year-old man who was shot outside an Edinburgh pub shortly before midnight on New Year's Eve. A second man injured during the incident has been taken to hospital. The deceased man is subsequently named as Marc Webley. 3 January – Police say they are "extremely concerned" for the safety of Laura Wilkie, a 43-year-old woman from Ayr, who has been missing since 18 December 2023. 4 January – Owners of American XL bully dogs in England and Wales are warned not to rehome them in Scotland as they become a banned breed under the Dangerous Dogs Act 1991 in England and Wales. Police searching for Laura Wilkie find a body at Rozelle Park in Ayr, close to where she was last seen. 5 January – Fugitive Nicholas Rossi, wanted in the United States on rape charges, is extradited from Scotland. 6 January – A 32-year-old man and 25-year-old woman have been arrested and charged with murder over the death of Marc Webley on New Year's Eve, police have confirmed. 8 January – Scottish Government papers reveal that a fragment of the Stone of Destiny gifted to Alex Salmond in 2008, and thought to be lost, is being held by the Scottish National Party at its headquarters. 9 January – BBC News reports that a ban on American XL bully dogs is likely in Scotland by the end of January.
Sources: en.wikipedia.org
The lawsuit was brought against VPX and its owner for claims of false advertising under the Lanham Act, California laws regarding unfair competition and false advertising, as well as trade libel. The jury issued the verdict on September 29, 2022. Following a trial lasting over a month, the jury awarded Monster Energy $293 million in damages. Among the damages were $272 million awarded for false advertising, $18 million for Bang's interference with contracts, and $3 million for trade secret theft. In October 2023, a judge awarded an additional $43 million dollars to Monster Energy for attorney fees and expenses.
The local Christian and Muslim community of Palestine, who constituted almost 90% of the population, strongly opposed the declaration. As described by the Palestinian-American philosopher Edward Said in 1979, it was perceived as being made: "(a) by a European power, (b) about a non-European territory, (c) in a flat disregard of both the presence and the wishes of the native majority resident in that territory, and (d) it took the form of a promise about this same territory to another foreign group." According to the 1919 King–Crane Commission, "No British officer, consulted by the Commissioners, believed that the Zionist programme could be carried out except by force of arms." A delegation of the Muslim-Christian Association, headed by Musa al-Husayni, expressed public disapproval on 3 November 1918, one day after the Zionist Commission parade marking the first anniversary of the Balfour Declaration. They handed a petition signed by more than 100 notables to Ronald Storrs, the British military governor:
In 1957, Marvin Margoshes and Bert L. Vallee at Harvard Medical School discovered that in horse kidney cortex, cadmium and zinc levels appeared to be maintained by binding to another molecule which they identified as a protein. They reported in the Journal of the American Chemical Society, concluding:The low sedimentation constant and high metal content of this material are indicative of a low molecular weight protein, probably containing a small number of cadmium atoms per molecule. Characterization of this unusual natural product is in progress.In 1958, Vallee presented the discovery at the International Congress of Biochemistry held in Vienna, and suggested that cadmium must be a natural biomolecule using the unknown protein. He pursued the research with his student Jeremias H. R. Kägi and was able to identify the new protein in 1960. The conclusion in The Journal of Biological Chemistry runs:The present study reports the isolation and characterization of a protein from equine renal cortex which contains 2.9% of cadmium, 0.6% of zinc, and 4.1% of sulfur per g dry weight of protein. This protein has been termed metallothionein in view of its metal and sulfur content.Vallee and Kägi reported further confirmation in the same journal in 1961. They later realised that metallothionein was not a single type of protein. With their collaborators, they could differentiate another related protein but with different amino acid properties and gave the name "metallothionein-1B" in 1970.
=== International perspective === Rhodesia's Unilateral Declaration of Independence from the United Kingdom on 11 November 1965 was promptly condemned by the international community. The United Nations Security Council Resolution 216 of 12 November 1965 called "upon all States not to recognise this illegal racist minority regime in Southern Rhodesia." Rhodesia campaigned for international acceptance and invoked the doctrine of non-intervention in internal affairs as justification for rebuking external criticism of its internal policies. However, the emerging doctrine of self-determination in colonial situations meant that most nations regarded Rhodesia's self-declared independence as illegitimate. Zambia, formerly Northern Rhodesia, took a pragmatic approach towards Rhodesia. Kenneth Kaunda, heavily dependent on access through Rhodesia for his nation's copper ore exports, fuel, and power imports unofficially worked with the Rhodesian government. Rhodesia still allowed Zambia to export and import its goods through its territory to Mozambique ports, despite the Zambian government's official policy of hostility and non-recognition of the post-UDI Smith Administration. The United States, like all other Western nations, refused to recognise Rhodesia, but unlike others allowed its Consulate-General to function as a communications conduit between the US government in Washington, DC and the Rhodesian government in Salisbury. When Rhodesia set up the Rhodesian Information Office in Washington, DC, OAS nations loudly protested.
==== MeSH D12.776.964.775.375 – gene products, pol (gene) ==== MeSH D12.776.964.775.375.325 – fusion proteins, gag-pol MeSH D12.776.964.775.375.335 – hiv integrase MeSH D12.776.964.775.375.340 – HIV protease MeSH D12.776.964.775.375.750 – RNA-directed DNA polymerase MeSH D12.776.964.775.375.750.375 – hiv-1 reverse transcriptase
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.